One in five Australian children start school with a speech or language disorder.

Some children will grow out of it, but others will go on to have persistent communication difficulties.

 

We know that speech and language disorders arise from genetic, neurological and environmental factors. Genetic factors are thought to play a significant role to speech and language.

 

We have recently identified that as many as 1 in 3 children with speech apraxia may receive a genetic diagnosis for their condition.

Our Latest News

Childhood Apraxia of Speech Trial

Childhood Apraxia of Speech Trial
We are trialling a new treatment for children with childhood apraxia of speech (CAS). This treatment is the drug methylphenidate (MPH), commonly known as Ritalin. We want to find out whether MPH can help improve the speech and language symptoms of CAS in children aged 6-12 years.
Hear Ms Lorraine O'Donnell, Registered Nurse and Coordinator of this trial, explain our study in this informative reel.
Dr Miya St John awarded a Harold Mitchell Foundation Travelling Fellowship

Dr Miya St John awarded a Harold Mitchell Foundation Travelling Fellowship

Dr Miya St John was awarded a Harold Mitchell Foundation Travelling Fellowship for her contribution to speech research.

The funding enables showcasing her research internationally & strengthen global collaborations.

Miya will use these funds to present at the International Koolen-de Vries Summit next July and learn a long-established therapy for Childhood Apraxia of Speech with our American colleagues.

Proudly in partnership with